Compare ARK Genomic Revolution ETF (ARKG) vs Carvana Co (CVNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Carvana Co — how do they compare? ARK Genomic Revolution ETF trades at $40.8, while Carvana Co trades at $65.14 (market cap $47.15B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| ARKG | CVNA | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $95.69 |
52-Week Low | $23.09 | $56.27 |
Market Cap | — | $47.15B |
Enterprise Value | — | $49.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Carvana (CVNA) trades at $65.83, down 1.92% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $20.32B in 2025 and net income of $1.41B, though Q2 2026 earnings are pending. Recent corporate actions include stock splits, and positive news highlights expansion into new-car sales and same-day delivery services. The stock shows improving cash flow trends, with operating cash flow reaching $1.04B in 2025.
Outlook: CVNA presents a mixed picture with robust revenue growth and profitability improvements offset by high valuation multiples and technical bearishness. Investment opportunity lies in continued operational scaling and market expansion, but risks include debt levels and competitive pressures. Analysts maintain a bullish consensus price target of $93.92, suggesting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
